Analysts expect that GW Pharmaceuticals PLC- (NASDAQ:GWPH) will report earnings per share (EPS) of ($0.13) for the current fiscal quarter, Zacks Investment Research reports. Six analysts have made estimates for GW Pharmaceuticals PLC-‘s earnings, with estimates ranging from ($1.80) to $1.68. GW Pharmaceuticals PLC- reported earnings per share of ($1.26) in the same quarter last year, which would suggest a positive year over year growth rate of 89.7%. The business is scheduled to announce its next quarterly earnings results on Tuesday, August 6th.

On average, analysts expect that GW Pharmaceuticals PLC- will report full year earnings of ($4.55) per share for the current financial year, with EPS estimates ranging from ($7.32) to $2.24. For the next fiscal year, analysts anticipate that the business will report earnings of ($0.44) per share, with EPS estimates ranging from ($2.79) to $5.88. Zacks’ earnings per share averages are an average based on a survey of analysts that follow GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last announced its earnings results on Monday, May 6th. The biopharmaceutical company reported ($1.68) EPS for the quarter, topping the consensus estimate of ($2.48) by $0.80. The company had revenue of $39.20 million for the quarter, compared to analysts’ expectations of $12.32 million. GW Pharmaceuticals PLC- had a negative return on equity of 45.75% and a negative net margin of 458.79%. The business’s revenue for the quarter was up 1189.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($3.12) earnings per share.

Several brokerages have recently commented on GWPH. ValuEngine cut GW Pharmaceuticals PLC- from a “strong-buy” rating to a “buy” rating in a report on Friday. BidaskClub upgraded GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a report on Thursday, May 9th. Oppenheimer cut GW Pharmaceuticals PLC- from an “outperform” rating to a “market perform” rating and set a $195.00 target price on the stock. in a report on Wednesday, May 8th. JPMorgan Chase & Co. upgraded GW Pharmaceuticals PLC- from a “market perform” rating to an “outperform” rating in a report on Wednesday, May 8th. Finally, Guggenheim restated a “buy” rating and set a $222.00 target price (up previously from $186.00) on shares of GW Pharmaceuticals PLC- in a report on Tuesday, May 7th. One research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $205.40.

In other news, insider Volker Knappertz sold 4,140 shares of the company’s stock in a transaction on Tuesday, February 26th. The stock was sold at an average price of $12.46, for a total transaction of $51,584.40. Following the transaction, the insider now owns 9,612 shares of the company’s stock, valued at $119,765.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Adam D. George sold 258,324 shares of the company’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $16.10, for a total value of $4,159,016.40. Following the transaction, the insider now directly owns 268,324 shares in the company, valued at approximately $4,320,016.40. The disclosure for this sale can be found here. Insiders have sold 3,005,064 shares of company stock worth $44,644,134 in the last ninety days. 5.50% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently modified their holdings of the company. US Bancorp DE lifted its stake in shares of GW Pharmaceuticals PLC- by 0.6% during the first quarter. US Bancorp DE now owns 11,683 shares of the biopharmaceutical company’s stock valued at $1,969,000 after acquiring an additional 75 shares during the period. Oppenheimer Asset Management Inc. lifted its stake in shares of GW Pharmaceuticals PLC- by 14.9% during the first quarter. Oppenheimer Asset Management Inc. now owns 601 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 78 shares during the period. Brandywine Oak Private Wealth LLC lifted its stake in shares of GW Pharmaceuticals PLC- by 6.0% during the first quarter. Brandywine Oak Private Wealth LLC now owns 1,435 shares of the biopharmaceutical company’s stock valued at $241,000 after acquiring an additional 81 shares during the period. Belpointe Asset Management LLC lifted its stake in shares of GW Pharmaceuticals PLC- by 6.2% during the fourth quarter. Belpointe Asset Management LLC now owns 1,463 shares of the biopharmaceutical company’s stock valued at $142,000 after acquiring an additional 85 shares during the period. Finally, Advisory Services Network LLC lifted its stake in shares of GW Pharmaceuticals PLC- by 23.1% during the fourth quarter. Advisory Services Network LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $50,000 after acquiring an additional 96 shares during the period. 79.60% of the stock is currently owned by institutional investors and hedge funds.

Shares of GWPH stock traded down $5.55 during trading hours on Tuesday, hitting $175.05. 410,018 shares of the company’s stock were exchanged, compared to its average volume of 470,429. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.19 and a current ratio of 7.81. The stock has a market capitalization of $5.28 billion, a PE ratio of -16.58 and a beta of 2.75. GW Pharmaceuticals PLC- has a 52 week low of $90.14 and a 52 week high of $196.00.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms.

Further Reading: Why do company’s buyback their stock?

Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- (GWPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.